| Literature DB >> 34213755 |
Elza Daoud1, Charlotte Caimino2,3, Michael A Akeroyd2, Arnaud J Noreña4, David M Baguley2,3,5.
Abstract
BACKGROUND AND OBJECTIVES: Tinnitus is a chronic subjective condition that impacts patients' health-related quality of life (HRQoL) and requires multidisciplinary interventions. In health economics, quality-adjusted life years (QALYs) and willingness to pay (WTP) are essential for evaluating treatment effectiveness in cost-effectiveness, cost-utility, or cost-benefit analysis. The extent to which these economic measures have been used in tinnitus research has not been investigated. The objectives of this scoping review were to explore findings and limitations of existing studies and provide an insight into how these economic measures could be used to quantify the burden of tinnitus in affected individuals.Entities:
Year: 2021 PMID: 34213755 PMCID: PMC8807799 DOI: 10.1007/s41669-021-00273-8
Source DB: PubMed Journal: Pharmacoecon Open ISSN: 2509-4262
Search term strategies for database searches
| MEDLINE, EMBASE and PsycINFO | CINAHL | |
|---|---|---|
| 1 | (economic OR economic analysis).ti,ab | Economic OR economic analysis |
| 2 | (willingness to pay OR wtp OR cost benefit OR cost effectiveness OR cost utility).ti,ab | Willingness to pay OR wtp OR cost benefit OR cost effectiveness OR cost utility |
| 3 | (time trade off OR tto OR standard gamble OR sg).ti,ab | Time trade off OR tto OR standard gamble OR sg |
| 4 | (QALY OR quality adjusted life years OR health valuation OR health utilit*).ti,ab | QALY OR quality adjusted life years OR health valuation OR health utilit* |
| 5 | (EuroQ*OR EQ 5D OR EQ 5D* OR EQ? 5D).ti,ab | EuroQ*OR EQ 5D OR EQ 5D* OR EQ? 5D |
| 6 | (HUI OR Health Utilities Index).ti,ab | HUI OR Health Utilities Index |
| 7 | (Quality of Wellbeing OR Quality of Well-Being OR QWB OR QWB-SA).ti,ab | Quality of Wellbeing OR Quality of Well-Being OR QWB OR QWB-SA |
| 8 | (AQoL OR assessment of quality of life).ti,ab | AQoL OR assessment of quality of life |
| 9 | (SF-6D OR SF6D).ti,ab | (SF-6D OR SF6D).ti,ab |
| 10 | (15D OR 16D OR 17D OR 15 dimensional OR 16 dimensional OR 17 dimensional).ti,ab | 15D OR 16D OR 17D OR 15 dimensional OR 16 dimensional OR 17 dimensional |
| 11 | 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 | 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 |
| 12 | tinnitus | tinnitus |
| 13 | 11 AND 12 | 11 AND 12 |
CINAHL Cumulative Index to Nursing and Allied Health Literature
Fig. 1 PRISMA flow chart of the study selection process. CINAHL Cumulative Index to Nursing and Allied Health Literature, PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses, QALY quality-adjusted life year, WTP willingness to pay
Demographics and characteristics of included articles
| References # | Authors | Date | Country | Measure | Study design | Type of tinnitus complaint | Age in years: | Sample size |
|---|---|---|---|---|---|---|---|---|
| [ | Engineer et al. | 2013 | USA | WTP | Cross-sectional | Non-specified | 47.4 25–65 | 439 |
| [ | Tyler | 2012 | USA | WTP | Cross-sectional | Non-specified | 66.4 31–90 | 197 |
| [ | Smit et al. | 2018 | The Netherlands | WTP | Cross-sectional | Non-specified | 58 (12) 18–64 | 415 |
| [ | Happich and Mazurek | 2002 | Germany | QALYs | Cross-sectional | Non-specified | 54 16–85 | 420 |
| [ | Happich and Muehlbacher | 2003 | ||||||
| [ | Happich and von Lengerke | 2005 | ||||||
| [ | Happich et al. | 2009 | ||||||
| [ | Cima et al. | 2012 | The Netherlands | QALYs | Randomised controlled trial | Tinnitus with subjective complaints | 54.19 (11.54) 20–85 | 428 |
| [ | Maes et al. | 2011 | ||||||
| [ | Maes et al. | 2014 | ||||||
| [ | Newman and Sandridge | 2012 | USA | QALYs | Retrospective between-subject clinical design | Tinnitus with subjective complaints | 53.5 29–77 | 56 |
| [ | Summerfield et al. | 2019 | UK | QALYs | Prospective, longitudinal study | Tinnitus associated with hearing impairments | 50.7 18.0–79.3 | 147 |
| [ | Stephens et al. | 2012 | Finland | QALYs | Cross-sectional | Tinnitus associated with Menière’s disease | 63 26–88 | 183 |
| [ | Robinson et al. | 2005 | USA | QALYs | Randomised controlled trial | Non-specified | 57 | 115 |
| [ | Robinson et al. | 2008 | USA | QALYs | Randomised controlled trial | Non-specified | 55 (11.28) 35–77 | 65 |
QALY quality-adjusted life year, WTP willingness to pay
Main findings and research gaps of included articles
| References # | Authors | Date | Measure | (i) Method/instrument used | (ii) Method used to determine tinnitus severity | Type of correlation between (i) and (ii) | Mean health state values |
|---|---|---|---|---|---|---|---|
| [ | Engineer et al. | 2013 | WTP | Close-ended questionnaire | VAS-Likert scale for loudness and annoyance | None was described | The most selected WTP category to reduce tinnitus by half was US$1000 for all respondents, and the most selected WTP to eliminate tinnitus was US$5000 |
| [ | Tyler | 2012 | WTP | Close-ended questionnaire | VAS for loudness and annoyance | A significantly low correlation between WTP to eliminate tinnitus and its loudness ( | |
| [ | Smit et al. | 2018 | WTP | Close-ended questionnaire | VAS for tinnitus burden, psychometric questionnaire (Mini-TQ) | A WTP of at least 20 times the monthly income was reported by the group of patients with the highest reported loudness | 58% of participants would be willing to pay more than their whole monthly income to cure tinnitus |
| [ | Happich and Mazurek | 2002 | QALYs | Direct PBMs: VAS, TTO, SG | None | None was described | At baseline, mean health state values were, respectively, VAS (0.53 vs 0.34), followed by SG (0.88 vs 0.80) and TTO (0.83 vs 0.78) |
| [ | Cima et al. | 2012 | QALYs | HUI3 | Psychometric questionnaires (THI, TQ, HADS, FTQ, TCCL, TCS) | None was described | Baseline utility scores were reported for two patient groups: 0.641 (0.295) and 0.628 (0.284) |
| [ | Maes et al. | 2011 | QALYs | HUI3 and EQ-5D | Psychometric questionnaire (TQ) | Both utility measures discriminate between clinically different groups. Groups with more severe tinnitus had significantly lower mean utility scores | Baseline utility scores with HUI3(0.63) were lower than with EQ-5D (0.77) |
| [ | Newman and Sandridge | 2012 | QALYs | Formula [ | Psychometric questionnaire (THI) | QALYs were calculated by multiplying life expectancy with the difference score (pre- and post-fitting) on the THI | None was reported |
| [ | Summerfield et al. | 2019 | QALYs | EQ-5D-3L, HUI2, HUI3, and SF-6D | Likert-based questionnaire | Change in tinnitus showed correlated with change in EQ-5D-3L ( | Utility scores were reported for patients with hearing impairment and tinnitus as a secondary complaint |
| [ | Stephens et al. | 2012 | QALYs | EQ-5D | Psychometric questionnaire (ITI) | EQ-5D TTO/VAS measures correlated significantly with the ITI ( | None was reported |
| [ | Robinson et al. | 2005 | QALYs | QWS | Psychometric questionnaire (THQ) | No significant correlation was found ( | Baseline utility scores were reported for two patient groups: 0.649 (SD = 0.107) and 0.651 (SD = 0.117) |
| [ | Robinson et al. | 2008 | QALYs | QWS | One-item Likert scale, psychometric questionnaires (THQ, TRQ, THI, TQ) | The benefits of this treatment were tinnitus specific and did not generalise to HRQoL | Baseline utility scores were reported for two patient groups: 0.49 (SD = 0.16) and 0.57 (SD = 0.13) |
EQ EuroQol, FTQ Fear of Tinnitus Questionnaire, HADS Hospital Anxiety and Depression Inventory, HRQoL health-related quality of life, HUI Health Utility Index, ITI International Tinnitus Inventory, Mini-TQ Mini-Tinnitus Questionnaire, PBM preference-based measure, QALY quality-adjusted life year, QWS Quality of Well-Being Scale, SF-6D Short Form 6D, SG standard gamble, TCCL tinnitus coping and cognitions list, TCS Tinnitus Catastrophising Scale, THI Tinnitus Handicap Inventory, THQ Tinnitus Handicap Questionnaire, TQ Tinnitus Questionnaire, TRQ Tinnitus Reaction Questionnaire, TTO time trade-off, VAS visual analogue scale, WTP willingness to pay
| Despite the high economic and societal burden of tinnitus, there is as yet no evidence to set the threshold for the reimbursement of available treatments. |
| More multidisciplinary studies assessing quality-adjusted life years and the willingness to pay of patients are needed to shed light on the burden of this disease, the utility of present treatments, and the benefit of novel treatments as they are developed. |